Dr An comes to Epitomics from Merck Research Laboratories, where he was director of biologics research. He has over 12 years of experience in drug discovery and development in the biotech and pharmaceutical industries, focusing on therapeutic antibody discovery, humanization and affinity maturation, preclinical and clinical development.
According to Epitomics, the addition of Dr An further sets the stage for the company to move aggressively into the human antibody therapeutic market starting with major preclinical work on multiple targets in 2009.
Guo-Liang Yu, CEO of Epitomics, said: “Dr An brings a wealth of knowledge and experience in antibody discovery, which he will leverage with Epitomics’ strong technologies and innovation to generate a pipeline of best-in-class antibody therapeutics focusing on clinically proven targets for broad therapeutic indications. We are delighted that he joins the executive management team at such a decisive stage of the company’s development.”